RLAY vs TEM
RLAY and TEM side by side — valuation & fundamentals (public data).
Key statistics
| Metric | RLAYRelay Therapeutics, Inc. | TEMTempus AI, Inc. |
|---|---|---|
| Market cap | $4.13B | $10.58M |
| P/B | — | 0.02 |
| P/S | 269.2x | 0.0x |
| Revenue | — | $1.43B(TTM) |
| Revenue growth (YoY) | 53.4% | 83.4% |
| Net income | — | -$254.40M(TTM) |
| Earnings growth (YoY) | 18.1% | 65.3% |
| EPS, diluted | — | $-1.44(TTM) |
| EBIT margin | -1971.6% | -19.9% |
| ROE | -31.1% | -55.1% |
| 1y total return | +357.8% | -33.7% |
Figures from SEC filings · for reference only · not investment advice
Growth of $10,000: RLAY vs TEM
| Metric | RLAY | TEM |
|---|---|---|
| End value | $25.8K | $14.7K |
| Total return | +158.1% | +46.6% |
| CAGR | +52.6% | +18.6% |
| Volatility | 78.7% | 97.4% |
| Sharpe | 0.86 | 0.61 |
| Sortino | 1.48 | 0.97 |
| Max drawdown | -79.0% | -59.8% |
Based on 562 common trading days, 2024-06-14 → 2026-09-11 · risk-free 4.07% (current short-Treasury, held constant)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)